Search

Displaying results 2031 - 2040 of 10000 in total
  1. Drug

    Esterified estrogens

    go.drugbank.com/drugs/DB09381
    Approved

    Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of menopause such as hot flashes, vaginal dryness, vaginal burning or irritation, or other hormonal changes in the … It is being also for the prevention and treatment of osteoporosis.

    Synonyms: Estrogens, Esterified Component of Menrium
  2. Drug

    Pentobarbital

    go.drugbank.com/drugs/DB00312
    ApprovedVet approved

    It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration.

    Categories: combinations of barbiturates
  3. Drug

    Bempedoic acid

    go.drugbank.com/drugs/DB11936
    ApprovedInvestigational

    Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease. … A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous

  4. Drug

    Zinc dibutyldithiocarbamate

    go.drugbank.com/drugs/DB14194
    Approved

    Zinc dibutyldithiocarbamate is a dermatological sensitizer and allergen. Sensitivity to zinc dibutyldithiocarbamate may be identified with a clinical patch test.

    Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use
  5. Drug

    Dactinomycin

    go.drugbank.com/drugs/DB00970
    ApprovedInvestigational

    A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. … It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release.

    Products: DACTINOMYCIN FOR INJECTION 0.5 mg/vial
  6. Drug

    Cenegermin

    go.drugbank.com/drugs/DB13926
    ApprovedInvestigational

    that the drug, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious condition. … [L4563] While the prevalence of neurotrophic keratitis is low, the impact of this serious condition and its associated sequelae on an individual patient can be debilitating.

  7. Drug

    Tixocortol

    go.drugbank.com/drugs/DB09091
    ApprovedWithdrawn

    Tixocortol is a 21-thiol derivative of hydrocortisone classified as a class A corticosteroid.

  8. Drug

    Iron protein succinylate

    go.drugbank.com/drugs/DB11209
    Approved

    Mixtures: FERPLEX FOL 40 MG + 0.185 MG/15 ML ORAL ÇÖZELTİ, 10 ADET, KOMFER FOL 40 MG/185 MCG ORAL COZELTI, 10 FLK.Products: FERPLEX 60 MG ORAL SOLÜSYON, 10 ADET, OLIGOFER 60 MG/22.5 ML ORAL ÇÖZELTI
  9. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    (ADCC), mediated by interactions between an antibody and Fcγ receptors on natural killer cells or macrophages. … [L44508] The next year, June 2023, ublituximab was also approved by the EMA for the treatment of relapsing forms of multiple sclerosis in adult patients.[L47486]

  10. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to

    Products: LORBRENA® 25 MG, LORBRENA® 100 MG